Belantamab
Blenrep (belantamab) is an antibody pharmaceutical. Belantamab was first approved as Blenrep on 2020-08-25. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target tumor necrosis factor receptor superfamily member 17.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| blenrep | Biologic Licensing Application | 2020-08-05 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9037 | Injection, belantamab mafodotin-blmf, 0.5 mg |
Clinical
Clinical Trials
48 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 3 | 3 | — | — | — | 3 | |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 3 | 3 | — | — | — | 3 |
| Blood protein disorders | D001796 | 3 | 3 | — | — | — | 3 | ||
| Plasma cell neoplasms | D054219 | 3 | 3 | — | — | — | 3 | ||
| Paraproteinemias | D010265 | D47.2 | 3 | 3 | — | — | — | 3 | |
| Corneal diseases | D003316 | H18.9 | 3 | 3 | — | — | — | 3 | |
| Immunoglobulin light-chain amyloidosis | D000075363 | 1 | 2 | — | — | — | 2 | ||
| Plasmablastic lymphoma | D000069293 | C83.3 | — | 1 | — | — | — | 1 | |
| Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BELANTAMAB |
| INN | belantamab |
| Description | Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2050232-20-5 |
| RxCUI | 2387844 |
| ChEMBL ID | CHEMBL4298208 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15719 |
| UNII ID | 7M3UL8MR2Y (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TNFRSF17
TNFRSF17
Organism
Homo sapiens
Gene name
TNFRSF17
Gene synonyms
BCM, BCMA
NCBI Gene ID
Protein name
tumor necrosis factor receptor superfamily member 17
Protein synonyms
B cell maturation antigen, B-cell maturation factor, B-cell maturation protein, CD269
Uniprot ID
Mouse ortholog
Tnfrsf17 (21935)
tumor necrosis factor receptor superfamily member 17 (O88472)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 627 documents
View more details
Safety
Black-box Warning
Black-box warning for: Blenrep
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
947 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more